Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Ketamine Stories

2013-03-26 23:03:19

Delray Recovery Center is a Florida facility that offers individualized treatment programs for drug addiction, alcohol addiction, eating disorders and co-occurring disorders such as bipolar disorder, depression and anxiety. In its ongoing efforts to increase awareness of drug abuse, the center is releasing an infographic outlining true facts about the drug ketamine. Delray Beach, FL (PRWEB) March 26, 2013 Although ketamine may be relatively new to the club drug scene, Delray Recovery...

2012-12-13 12:29:17

Works in brain like ketamine, with fewer side effects -- NIH trial A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system. Existing antidepressants available through...

2012-12-11 08:24:39

CARDIFF, Calif., Dec. 11, 2012 /PRNewswire/ -- NI Research has released the December issue of NeuroPerspective, which features a comprehensive review of pharmacotherapies for depression, with a particular focus upon the programs developing RAADs, rapid-acting antidepressants, an approach that springs from the reports of accelerated depression relief via the use of ketamine. This 29-page issue includes:1) An overview of the biology of depression and the implications of accelerated treatment...

2012-12-06 08:26:22

HOLLYWOOD, Fla. and EVANSTON, Ill., Dec. 6, 2012 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported positive results from a Phase IIa clinical trial of its lead antidepressant compound, GLYX-13. GLYX-13 is a novel partial agonist of the NMDA receptor. The Phase Ila results are being presented this week at the 51(st) Annual Meeting of the American College of Neuropsychopharmacology (ACNP)....

2012-12-05 08:26:31

SAN DIEGO, Nov. 5, 2012 /PRNewswire/ -- BrainCells, Inc. (BCI), a leading biotechnology company developing novel compounds for the treatment of central nervous system (CNS) diseases, announced the successful completion of their Phase 1 multiple ascending dose (MAD) study of BCI-838, the oral prodrug for the company's Group II mGluR2/3 antagonist, BCI-632. BCI will advance the clinical development program of the compound by initiating a Proof-of-Concept (PoC) study in patients with...

2012-10-05 14:23:56

Raises hopes for new class of antidepressant Many chronically depressed and treatment-resistant patients experience immediate relief from symptoms after taking small amounts of the drug ketamine. For a decade, scientists have been trying to explain the observation first made at Yale University. Today, current evidence suggests that the pediatric anesthetic helps regenerate synaptic connections between brain cells damaged by stress and depression, according to a review of scientific...

2012-08-07 23:17:46

Biomarkers help pinpoint mechanisms, predict outcomes -- NIH studies Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers. The signal is among the latest of several such markers, including...

Common Cat Anesthetic Used To Treat Depressed Patients
2012-05-31 04:12:00

Ketamine, an anesthetic commonly used in veterinary practice for feline surgical procedures, has been found to help bipolar patients suffering from depression. Researchers at the National Institute of Mental Health had previously found that a single dose of ketamine produced rapid antidepressant effects in depressed patients with bipolar disorder. The team has now replicated that finding in an independent group of depressed patients, who also had bipolar disorder. During the new...

2012-05-17 02:26:06

DALLAS, May 17, 2012 /PRNewswire/ -- The "Anesthesia Drugs Market (2011 - 2015) - U.S. Market Entry Study [http://www.marketsandmarkets.com/Market-Reports/anesthesia-drugs-ketamine-market-713.html ] " analyzes and studies the U.S. market for intravenous anesthesia drugs with special focus on ketamine, distribution structure of anesthesia drugs in U.S., potential buyers, export & import system for controlled substances in U.S. and U.S. market entry strategy. Browse...

2012-05-08 10:51:51

One of these new abused drugs is methoxetamine (MXE), sold as a “legal” alternative to ketamine A group of researchers from the IMIM (Hospital del Mar Research Institute) and from the INAD (Hospital del Mar Neuropsychiatry and Addictions Institute) has participated in an international study aiming to give a general overview at a chemical, pharmacological and behavioral level of a recently appeared new chemical compound, according to the Recreational Drugs European Network, as a...